Effect of losartan on TGF‐β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

Abstract

Treatment with losartan decreases TGF-beta1 plasma values and UAE in type 2 diabetes mellitus patients with high baseline TGF-beta1 levels, suggesting that TGF-beta1 may be a marker to detect patients who may particularly benefit from renin-angiotensin system blockade.